A 39-year-old man with a skin infection

JAMA

Volumn 299, Issue 1, 2008, Pages 79-87

  Moellering, Robert C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MINOCYCLINE; PENICILLIN DERIVATIVE; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; DRUG COST; ERYTHEMA; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; SKIN INFECTION; SKIN SWELLING; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES;

EID: 38049018068     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.21.jrr70002     Document Type: Article

References (81)

1. Swartz MN. Cellulitis. N Engl J Med. 2004;350(9):904-912.
2. Swartz MN, Pasternack MS. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:1172-1194.
3. Goldstein EJC. Bites. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:3552-3556.
4. Goldstein EJC, Citron DM, Richwald GA. Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida. Antimicrob Agents Chemother. 1988;32(2):213-215.
5. Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. J Med Microbiol. 1999;48(9):789-799.
6. Reboli AC, Farrar WE. Erysipelothrix rhusiopathiae. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:2496-2498.
7. Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA. Syndromes of Vibrio vulnificus infections: clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. 1988;109(4):318-323.
8. Gold WL, Salit IE. Aeromonas hydrophila infections of skin and soft tissue: report of 11 cases and review. Clin Infect Dis. 1993;16(1):69-74.
9. Baker AS, Ruoff KL, Madoff S. Isolation of Mycoplasma species from a patient with seal finger. Clin Infect Dis. 1998;27(5):1168-1170.
10. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis. N Engl J Med. 1986;315(2):91-96.
11. Tacconelli E, Carmeli Y, Aizer A, et al. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis. 2003;37(12):1629-1638.
12. White A. Increased infection rates in heavy nasal carriers of coagulase-positive staphylococci. Antimicrobial Agents Chemother (Bethesda). 1963;161:667-670.
13. Sheagren JN. Staphylococcus aureus: the persistent pathogen (first of two parts). N Engl J Med. 1984;310(21):1368-1373.
14. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520-532.
15. Rimland D, Roberson B. Gastrointestinal carriage of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 1986;24(1):137-138.
16. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352(5):468-475.
17. Müller-Premru M, Strommenger B, Alikadic N, et al. New strains of community-acquired methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin causing an outbreak of severe soft tissue infection in a football team. Eur J Clin Microbiol Infect Dis. 2005;24(12):848-850.
18. Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int. 2001;21(6):554-559.
19. Berger RS, Seifert MR. Whirlpool folliculitis: a review of its cause, treatment, and prevention. Cutis. 1990;45(2):97-98.
20. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37(11):1405-1433.
21. Schneider-Lindner V, Delaney JA, Dial S, Dascal A, Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis. 2007;13(7):994-1000.
22. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet. 2001;357(9264):1225- 1240.
23. Moellering RC Jr, Murray BE. Mechanisms of antibiotic resistance. Guidelines to Antibiotic Therapy. 1979;5:1-3.
24. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med. 1989;320(18):1188-1196.
25. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother. 1989;33(7):991-994.
26. Chongtrakool P, Ito T, Ma XX, et al. Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother. 2006;50(3):1001-1012.
27. National Nosocomial Infections Surveillance System data. http://www.cdc.gov/ncidod/dhqp/pdf/ar/ICU_RESTrend 1995-2004.pdf. Accessed January 2006.
28. Hsu CCS, Macaluso CP, Special L, Hubble RH. High rate of methicillin resistance of Staphylococcus aureus isolated from hospitalized nursing home patients. Arch Intern Med. 1988;148(3):569-570.
29. Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak. Ann Intern Med. 1982;96(1):11-16.
30. Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982;97(3):330-338.
31. Craven DE, Rixinger AI, Goularte TA, McCabe WR. Methicillin-resistant Staphylococcus aureus bacteremia linked to intravenous drug abusers using a "shooting gallery." Am J Med. 1986;80(5):770-776.
32. Maguire GP, Arthur A, Boustead P, Dwyer B, Currie B. Clinical experience and outcomes of community-acquired and nosocomial methicillin-resistant Staphylococcus aureus in a northern Australian hospital. J Hosp Infect. 1998;38(4):273-281.
33. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota. MMWR Morb Mortal Wkly Rep. 1999;48:707-710.
34. Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus [published correction appears in N Engl J Med. 2007;357(13):1357]. N Engl J Med. 2007;357(4):380-390.
35. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40(12):1785-1791.
36. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309-317.
37. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
38. Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med. 2006;119(11):943-951.
39. Klevens RM, Morrrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763-1771.
40. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med. 2006;144(5):368-370.
41. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753-759.
42. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis. 2006;194(12):1761- 1770.
43. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130-1133.
44. Tenover FC. Community-associated methicillin-resistant Staphylococcus aureus: it's not just in communities anymore. Clin Microbiol Newsl. 2005;25:33-37.
45. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol. 2006;44(1):108-118.
46. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006;193(2):172-179.
47. Naimi TS, DeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976-2984.
48. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO Jr, Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43(8):953-960.
49. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353(12):1245-1251.
50. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-107.
51. Banthia S, Meka VG, Pillai S, et al. A fatal case of necrotizing pneumonia caused by community-associated methicillin-resistant Staphylococcus aureus. Infect Dis Clin Pract. 2005;13:132-138.
52. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.
53. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital-and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2006;193(11):1495-1503.
54. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007;45(4):1350-1352.
55. Eron LJ, Lipsky BA. Use of cultures in cellulitis: when, how and why? Eur J Clin Microbiol Infect Dis. 2006;25(10):615-617.
56. Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA, eds. The Sanford Guide to Antimicrobial Therapy. 37th ed. Sperryville, VA: Antimicrobial Therapy Inc; 2007.
57. Szumowski JD, Cohen DE, Fumihide K, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007;51(2):423-428.
58. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(7):2628-2630.
59. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40(10):1429-1434.
60. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis. 2003;37(9):1257-1260.
61. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004;188(6):760-766.
62. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis. 2006;42(suppl 1):S40-S51.
63. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect. 2006;12(suppl 1):24-32.
64. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658-4666.
65. Treatment of community-associated MRSA infections. Med Lett Drugs Ther. 2006;48(1228):13-14.
66. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135-142.
67. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51(11):4044-4048.
68. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117(5):390-398.
69. Kaka AS, Rueda AM, Shelburne SA III, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58(3):680-683.
70. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother. 2001;48(2):315-316.
71. Levin TP, Suh B, Axelrod P, Truant AL, Fekete T. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother. 2005;49(3):1222-1224.
72. Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(6):785-787.
73. Moellering RC Jr, Linden PK, Reinhardt MDJ, et al. The efficacy and safety of quinupristin/dalfopristin (Synercid) for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1999;44(2):251-261.
74. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2004;38(12):1673-1681.
75. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infection. Clin Infect Dis. 2005;41(10):1407-1415.
76. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26(5):511-532.
77. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862-867.
78. Noel GJ. Clinical profile of ceftobiprole, a novel β-lactam antibiotic. Clin Microbiol Infect. 2007;13(suppl 2):25-29.
79. Jacqueline C, Grossi O, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA): comparison with vancomycin (VAN) and linezolid (LZO) in a rabbit endocarditis model (REM). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 20-27, 2006; San Francisco, CA. Abstract B-1819.
80. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol. 1989;27(2):335-336.
81. Holland SM, Gallin JI. Evaluation of the patient with suspected immunodeficiency. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:149-160.